NewsRx

Search our medical news database

Biogen Idec Inc.

Biogen Idec Reiterates Proposal to Acquire All Outstanding Shares of Facet for $14.50 Per Share in Cash

Published in Healthcare Mergers, Acquisitions and Ventures Week, September 26th, 2009

Biogen Idec Inc. (NASDAQ:BIIB) today reiterated its proposal to acquire all of the outstanding shares of Facet Biotech Corporation for $14.50 per share in cash.

James C. Mullen, Biogen Idec's President and Chief Executive Officer, stated, "We continue to believe that Biogen Idec's $14.50 per share, all-cash offer represents an extremely attractive opportunity for Facet's shareholders to realize today the future value of their company. The price we are offering ascribes meaningful and appropriate value to the company's clinical programs while taking into account Facet's significant building lease and other obligations, and recently announced collaboration agreement with...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook